| GSGSX | VVIAX | GSGSX / VVIAX | |
| Total Expense Ratio | 1.19 | 0.05 | 2,380% |
| Annual Report Gross Expense Ratio | 1.33 | 0.05 | 2,660% |
| Fund Existence | 33 years | 25 years | - |
| Gain YTD | 4.564 | 5.999 | 76% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 3000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 431M | 218B | 0% |
| Annual Yield % from dividends | 0.73 | 1.95 | 37% |
| Returns for 1 year | 3.59 | 15.08 | 24% |
| Returns for 3 years | 18.29 | 41.04 | 45% |
| Returns for 5 years | 25.92 | 66.27 | 39% |
| Returns for 10 years | 98.20 | 167.18 | 59% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| HRMDX | 14.24 | 0.21 | +1.50% |
| Heartland Mid Cap Value Investor | |||
| NAIGX | 40.34 | 0.32 | +0.80% |
| Nuveen International Value A | |||
| VSCPX | 376.44 | 0.47 | +0.13% |
| Vanguard Small Cap Index InstlPlus | |||
| TRWTX | 26.70 | -0.01 | -0.04% |
| Transamerica International Equity I3 | |||
| RYBOX | 63.69 | -0.09 | -0.14% |
| Rydex Biotechnology A | |||